Suppr超能文献

脂质结合区域(2303 - 2332)参与重组人凝血因子VIII(rFVIII)的聚集。

Lipid binding region (2303-2332) is involved in aggregation of recombinant human FVIII (rFVIII).

作者信息

Ramani Karthik, Purohit Vivek S, Miclea Razvan D, Middaugh C Russell, Balasubramanian Sathyamangalam V

机构信息

Department of Pharmaceutical Sciences, University at Buffalo, State University of New York, Amherst, NY 14260, USA.

出版信息

J Pharm Sci. 2005 Jun;94(6):1288-99. doi: 10.1002/jps.20340.

Abstract

Factor VIII (FVIII) is a multi-domain protein that is important in the clotting cascade. Its deficiency causes Hemophilia A, a bleeding disorder. The unfolding of protein domains can lead to physical instability such as aggregation, and hinder their use in replacement therapy. It has been shown that the aggregation of rFVIIII is initiated by small fluctuations in the protein's tertiary structure (Grillo et al., 2001, Biochemistry 40:586-595). We have investigated the domain(s) involved in the initiation of aggregation using circular dichroism (CD), size exclusion chromatography (SEC), fluorescence anisotropy, domain specific antibody binding, and clotting activity studies. The studies indicated that aggregation may be initiated as a result of conformational change in the C2 domain encompassing the lipid-binding region (2303-2332). The presence of O-phospho-L-Serine (OPLS), which binds to the lipid-binding region of FVIII, prevented aggregation of the protein.

摘要

凝血因子VIII(FVIII)是一种多结构域蛋白,在凝血级联反应中起重要作用。其缺乏会导致A型血友病,一种出血性疾病。蛋白质结构域的展开会导致物理不稳定性,如聚集,并阻碍其在替代疗法中的应用。研究表明,重组FVIII的聚集是由蛋白质三级结构的微小波动引发的(Grillo等人,2001年,《生物化学》40:586 - 595)。我们使用圆二色性(CD)、尺寸排阻色谱(SEC)、荧光各向异性、结构域特异性抗体结合和凝血活性研究,对参与聚集起始的结构域进行了研究。研究表明,聚集可能是由于包含脂质结合区域(2303 - 2332)的C2结构域的构象变化而引发的。与FVIII脂质结合区域结合的O - 磷酸 - L - 丝氨酸(OPLS)的存在可防止该蛋白聚集。

相似文献

2
Aggregation kinetics of recombinant human FVIII (rFVIII).
J Pharm Sci. 2005 Sep;94(9):2023-9. doi: 10.1002/jps.20432.
4
5
Lower inhibitor development in hemophilia A mice following administration of recombinant factor VIII-O-phospho-L-serine complex.
J Biol Chem. 2005 May 6;280(18):17593-600. doi: 10.1074/jbc.M500163200. Epub 2005 Feb 23.
10
Conformational origin of the aggregation of recombinant human factor VIII.
Biochemistry. 2001 Jan 16;40(2):586-95. doi: 10.1021/bi001547t.

引用本文的文献

2
Tolerogenic form of Factor VIII to prevent inhibitor development in the treatment of Hemophilia A.
J Thromb Haemost. 2021 Nov;19(11):2744-2750. doi: 10.1111/jth.15497. Epub 2021 Sep 1.
3
5
Native-like aggregates of factor VIII are immunogenic in von Willebrand factor deficient and hemophilia a mice.
J Pharm Sci. 2012 Jun;101(6):2055-65. doi: 10.1002/jps.23091. Epub 2012 Mar 2.
8
Delivery of therapeutic proteins.
J Pharm Sci. 2010 Jun;99(6):2557-75. doi: 10.1002/jps.22054.
10
Development and characterization of lipidic cochleate containing recombinant factor VIII.
Biochim Biophys Acta. 2007 Nov;1768(11):2890-8. doi: 10.1016/j.bbamem.2007.08.001. Epub 2007 Aug 19.

本文引用的文献

3
Topology of factor VIII bound to phosphatidylserine-containing model membranes.
Biochim Biophys Acta. 2003 Oct 31;1617(1-2):31-8. doi: 10.1016/j.bbamem.2003.08.012.
5
Correlation of rFVIII inactivation with aggregation in solution.
Pharm Res. 2003 Apr;20(4):693-700. doi: 10.1023/a:1023271405005.
6
Molecular characterization of the immune response to factor VIII.
Vox Sang. 2002 Aug;83 Suppl 1:403-8. doi: 10.1111/j.1423-0410.2002.tb05342.x.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验